eligibility_summary
Eligible: adults (≥18) needing labeled biologic therapy for CRSwNP, includes those treated since Aug 2021 (retrospective data). Exclude: oral corticosteroids in past month, biologics (anti-IgE, anti-IL-5/5R, anti-IL-4/13R or other) in past 6 months unless ongoing for severe asthma/CRSwNP, hypersensitivity to humanized antibodies, COVID-19 with persistent smell disorder in past 3 months, pregnant/breastfeeding, no social coverage.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
French real‑world registry in severe chronic rhinosinusitis with nasal polyps assessing biologic treatments: dupilumab, mepolizumab, and benralizumab (subcutaneous). Dupilumab: monoclonal antibody against IL‑4Rα, blocking IL‑4/IL‑13 signaling to suppress type‑2 (Th2) inflammation, reducing IgE class switching, mucus production, and eosinophil trafficking. Mepolizumab: anti‑IL‑5 monoclonal antibody that neutralizes IL‑5, lowering eosinophil maturation, survival, and recruitment. Benralizumab: afucosylated anti‑IL‑5Rα monoclonal antibody depleting eosinophils (and basophils) via ADCC. Targeted cells/pathways: Th2 cytokine axis (IL‑4/IL‑13/IL‑5), eosinophils, basophils, and downstream B‑cell/IgE responses.